Literature DB >> 33547226

Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling.

Elisa Landoni1, Giovanni Fucá1, Jian Wang2, Venkat R Chirasani2, Zhiyuan Yao3,4, Elena Dukhovlinova1, Soldano Ferrone5, Barbara Savoldo1,6, Lee K Hong1, Peishun Shou1, Silvia Musio7, Francesco Padelli8, Gaetano Finocchiaro7, Miriam Droste9, Brian Kuhlman1,3, Abdijapar Shamshiev9, Serena Pellegatta7, Nikolay V Dokholyan2, Gianpietro Dotti10,11.   

Abstract

Chimeric antigen receptor (CAR) tonic signaling, defined as spontaneous activation and release of proinflammatory cytokines by CAR-T cells, is considered a negative attribute because it leads to impaired antitumor effects. Here, we report that CAR tonic signaling is caused by the intrinsic instability of the mAb single-chain variable fragment (scFv) to promote self-aggregation and signaling via the CD3ζ chain incorporated into the CAR construct. This phenomenon was detected in a CAR encoding either CD28 or 4-1BB costimulatory endodomains. Instability of the scFv was caused by specific amino acids within the framework regions (FWR) that can be identified by computational modeling. Substitutions of the amino acids causing instability, or humanization of the FWRs, corrected tonic signaling of the CAR, without modifying antigen specificity, and enhanced the antitumor effects of CAR-T cells. Overall, we demonstrated that tonic signaling of CAR-T cells is determined by the molecular instability of the scFv and that computational analyses of the scFv can be implemented to correct the scFv instability in CAR-T cells with either CD28 or 4-1BB costimulation. ©2021 American Association for Cancer Research.

Entities:  

Year:  2021        PMID: 33547226     DOI: 10.1158/2326-6066.CIR-20-0451

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  6 in total

Review 1.  CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a sweet success?

Authors:  Pooria Safarzadeh Kozani; Pouya Safarzadeh Kozani; Fatemeh Rahbarizadeh
Journal:  Front Med       Date:  2022-06-10       Impact factor: 9.927

Review 2.  In Like a Lamb; Out Like a Lion: Marching CAR T Cells Toward Enhanced Efficacy in B-ALL.

Authors:  Pouya Safarzadeh Kozani; Pooria Safarzadeh Kozani; Roddy S O'Connor
Journal:  Mol Cancer Ther       Date:  2021-04-26       Impact factor: 6.009

Review 3.  CAR-T cell potency: from structural elements to vector backbone components.

Authors:  Marzieh Mazinani; Fatemeh Rahbarizadeh
Journal:  Biomark Res       Date:  2022-09-19

4.  Engineering a natural ligand-based CAR: directed evolution of the stress-receptor NKp30.

Authors:  Savannah E Butler; Rachel A Brog; Cheryl H Chang; Charles L Sentman; Yina H Huang; Margaret E Ackerman
Journal:  Cancer Immunol Immunother       Date:  2021-05-27       Impact factor: 6.968

5.  Fully human antibody VH domains to generate mono and bispecific CAR to target solid tumors.

Authors:  Guanmeng Wang; Xin Zhou; Giovanni Fucà; Elena Dukhovlinova; Peishun Shou; Hongxia Li; Colette Johnston; Brian Mcguinness; Gianpietro Dotti; Hongwei Du
Journal:  J Immunother Cancer       Date:  2021-04       Impact factor: 13.751

Review 6.  NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development.

Authors:  Ali Bashiri Dezfouli; Mina Yazdi; Alan Graham Pockley; Mohammad Khosravi; Sebastian Kobold; Ernst Wagner; Gabriele Multhoff
Journal:  Cells       Date:  2021-12-01       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.